Novartis aiming to expand patient reach for world’s most expensive drug, Zolgensma
The US FDA's clinical hold on Zolgensma did not just delay Novartis in developing the drug, but allowed its competitors…
By
Musculoskeletal Disorders
Latest in
Musculoskeletal Disorders
argenx reports positive data of efgartigimod in myasthenia gravis trial
The Phase III trial met the primary endpoint with efgartigimod showing improvement in the quality of life of patients.
Janssen presented new Tremfya data at EULAR 2021
Recent trial results position Janssen's Tremfya well in the psoriatic arthritis market, but the drug still faces strong competition.
By
AAN 2021: Sarepta’s SRP-9001 set to redeem its prospects in DMD
Sarepta Therapeutics presented interim findings from its Phase II clinical trial (Study 102) in Duchenne muscular dystrophy (DMD) for its…
By
Long-term data from Roche’s Evrysdi will consolidate its strong position in SMA market
Two-year data from part two of FIREFISH, a Phase II/III global study by Roche evaluating Evrysdi (risdiplam) in infants aged…
By
ARN launches new patient centric unit for rheumatology trials
American Rheumatology Network (ARN) has launched ARN Clinical Research, a patient centric and real-world technology unit for transforming rheumatology trials…
Horizon Therapeutics enrols first subject in uncontrolled gout trial
Horizon Therapeutics has enrolled the first patient in a clinical trial of Krystexxa (pegloticase injection) plus methotrexate for treating people…
Roche reports positive data from SMA treatment trial
Roche has reported positive data from the dose finding Part I FIREFISH study of Evrysdi (risdiplam) in infants with symptomatic…